



**Cancer Antigen 125 (CA-125)  
Test System  
Product Code: 3025-300**

**1.0 INTRODUCTION**

**Intended Use: The Quantitative Determination of Cancer Antigen 125 (CA-125) Concentration in Human Serum by a Microplate Enzyme Immunoassay, Colorimetric**

**2.0 SUMMARY AND EXPLANATION OF THE TEST**

Cancer Antigen 125 (CA-125) is a glycoprotein that occurs in blood as high molecular weight entity ( $M_{r} > 200,000$ ). High concentrations of this antigen are associated with ovarian cancer and a range of benign and malignant diseases. Although the specificity and sensitivity of CA-125 assays are somewhat limited, especially in early diagnosis of ovarian cancer, the assay has found widespread use in the differential diagnosis of adnexal masses, in monitoring disease progression and response to therapy in ovarian cancer, and in the early detection of recurrence after surgery or chemotherapy for ovarian cancer. Published literature has shown that elevated serum CA-125 levels can be observed in patients with serious endometrioid, clear cell and undifferentiated ovarian carcinoma. The serum CA-125 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-neoplastic conditions (including, but not limited to, first trimester pregnancy, menstruation, endometriosis uterine fibrosis, acute salpingitis, hepatic diseases and inflammation of peritoneum or pericardium).

In this method, CA-125 calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies (directed against distinct and different epitopes of CA-125) are added and the reactants mixed. Reaction between the various CA-125 antibodies and native CA-125 forms a sandwich complex that binds with the streptavidin coated to the well.

After the completion of the required incubation period, the enzyme-CA-125 antibody bound conjugate is separated from the unbound enzyme-CA-125 conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.

The employment of several serum references of CA-125 levels permits the construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with CA-125 concentration.


**3.0 PRINCIPLE**

**Immunoenzymometric assay (TYPE 3):**


The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, in

excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-CA-125 antibody.

Upon mixing monoclonal biotinylated antibody, the enzyme-labeled antibody and a serum containing the native antigen, a reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. The interaction is illustrated by the following equation:



Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below:



After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

**4.0 REAGENTS**

**Materials Provided:**

- A. CA-125 Calibrators - 1ml/vial- Icons A-F**  
Six (6) vials of references CA-125 Antigen at levels of 0(A), 15(B), 50(C), 100(D), 200(E) and 400(F) U/ml. A preservative has been added. Store at 2-8°C.
- Note:** The human serum based standards were made using a >99% pure affinity purified preparation of CA-125. The preparation was calibrated against Centocor CA-125 IRMA test.
- B. CA-125 Enzyme-Reagent – 13ml/vial - Icon**   
One (1) vial containing enzyme labeled antibody, biotinylated monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8°C.
- C. Streptavidin Coated Plate – 96 wells – Icon**   
One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
- D. Wash Solution Concentrate – 20ml/vial - Icon**   
One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- E. Substrate A – 7ml/vial - Icon**   
One (1) vial containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C. See "Reagent Preparation."
- F. Substrate B – 7ml/vial - Icon**   
One (1) vial containing hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in buffer. Store at 2-8°C. See "Reagent Preparation."
- G. Stop Solution – 8ml/vial - Icon**   
One (1) vial containing a strong acid (1N HCl). Store at 2-8°C.

**H. Product Instructions.**

- Note 1:** Do not use reagents beyond the kit expiration date.
- Note 2:** Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.**
- Note 3:** Above reagents are for a single 96-well microplate

**4.1 Required But Not Provided:**

- 1. Pipette capable of delivering 0.025 & 0.050ml (25 & 50µl) volumes with a precision of better than 1.5%.

- 2. Dispenser(s) for repetitive deliveries of 0.100 & 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
- 3. Microplate washers or a squeeze bottle (optional).
- 4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- 5. Absorbent Paper for blotting the microplate wells.
- 6. Plastic wrap or microplate cover for incubation steps.
- 7. Vacuum aspirator (optional) for wash steps.
- 8. Timer.
- 9. Quality control materials

**5.0 PRECAUTIONS**

**For In Vitro Diagnostic Use  
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe disposal of kit components must be according to local regulatory and statutory requirement.**

**6.0 SPECIMEN COLLECTION AND PREPARATION**

The specimens shall be blood serum and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells.

**In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.**

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50µl) of the specimen is required.

**7.0 QUALITY CONTROL**

Each laboratory should assay controls at levels in the low, medium and elevated ranges of the dose response curve for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

**8.0 REAGENT PREPARATION**

- 1. Wash Buffer**  
Dilute contents of wash solution to 1000ml with distilled or deionized water in a suitable storage container. Store diluted buffer at 2-30°C for up to 60 days.
- 2. Working Substrate Solution – Stable for one (1) year**  
Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.

**Note1: Do not use the working substrate if it looks blue.  
Note 2: Do not use reagents that are contaminated or have bacteria growth.**

**9.0 TEST PROCEDURE**

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C).  
\*\*Test procedure should be performed by a skilled individual or trained professional\*\**

- 1. Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- 2. Pipette 0.025ml (25µl) of the appropriate serum reference calibrator, control or specimen into the assigned well.
- 3. Add 0.100ml (100µl) of the CA-125 Enzyme Reagent to each well. **It is very important to dispense all reagents close to the bottom of the coated well.**
- 4. Swirl the microplate gently for 20-30 seconds to mix and cover.
- 5. Incubate 60 minutes at room temperature.
- 6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper.
- 7. Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- 8. Add 0.100ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**  
**DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
- 9. Incubate at room temperature for fifteen (15) minutes.
- 10. Add 0.050ml (50µl) of stop solution to each well and mix gently for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells.**
- 11. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. **The results should be read within thirty (30) minutes of adding the stop solution.**

**10.0 CALCULATION OF RESULTS**


A dose response curve is used to ascertain the concentration of CA-125 in unknown specimens.

- 1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- 2. Plot the absorbance for each duplicate serum reference versus the corresponding CA-125 concentration in U/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
- 3. Draw the best-fit curve through the plotted points.
- 4. To determine the concentration of CA-125 for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in U/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (0.3311) intersects the dose response curve at 29.3U/ml CA-125 concentration (See Figure 1).

**Note:** Computer data reduction software designed ELISA assays may also be used for the data reduction. *If such software is utilized, the validation of the software should be ascertained.*

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (U/ml)
Cal A	A1	0.035	0.029	0
	B1	0.022		
Cal B	C1	0.186	0.182	15
	D1	0.178		
Cal C	E1	0.536	0.545	50
	F1	0.554		
Cal D	G1	0.985	0.967	100
	H1	0.949		
Cal E	A2	1.615	1.615	200
	B2	1.616		
Cal F	C2	2.749	2.753	400
	D2	2.758		
Patient	A3	0.336	0.331	29.3
	B3	0.325		

Figure 1



\*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay.

### 11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator F should be  $\geq 1.3$
2. Four out of six quality control pools should be within the established ranges.

### 12.0 RISK ANALYSIS

#### 12.1 Assay Performance

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Patient specimens with CA-125 concentrations above 400 U/ml may be diluted (for example 1/10 or higher) with normal male serum (CA-125 < 5 U/ml) and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor (10).
10. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind's IFU may yield inaccurate results.

11. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
12. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
13. Risk Analysis - as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from [Monobind@monobind.com](mailto:Monobind@monobind.com).

#### 12.2 Interpretation

1. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
2. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
3. The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988;34:27-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
4. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability**.
5. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
6. CA-125 has a low clinical sensitivity and specificity as a tumor marker. Clinically an elevated CA-125 value alone is not of diagnostic value as a test for cancer and should only be used in conjunction with other clinical manifestations (observations) and diagnostic parameters.

### 13.0 EXPECTED RANGE OF VALUES

The serum CA-125 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases and 6% of patients with non-neoplastic conditions (including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, acute salpingitis, hepatic diseases and inflammation of peritoneum or pericardium).

Healthy and non-pregnant subjects	U <sub>g</sub> ≤ 35 U/ml
-----------------------------------	--------------------------

It is important to keep in mind that establishment of a range of values, which can be expected to be found by a given method for a population of "normal" persons, is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons, each laboratory should depend upon the range of expected values established by the Manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

### 14.0 PERFORMANCE CHARACTERISTICS

#### 14.1 Precision

The within and between assay precisions of the CA-125 AccuBind® ELISA test system were determined by analyses on three different levels of control sera. The number (N), mean value (X), standard deviation ( $\sigma$ ) and coefficient of variation (C.V.) for each of these control sera are presented in Table 2 and Table 3.

Sample	N	X	$\sigma$	C.V.
Level 1	20	3.1	0.22	7.1%
Level 2	20	28.0	1.42	5.0%
Level 3	20	161.2	4.21	2.6%

Sample	N	X	$\sigma$	C.V.
Level 1	10	3.7	0.44	11.8%
Level 2	10	25.3	1.81	7.1%
Level 3	10	154.0	5.11	3.4%

\*As measured in ten experiments in duplicate.

#### 14.2 Sensitivity

The CA-125 AccuBind® ELISA test system has a sensitivity of 1.0 U/ml. The sensitivity was ascertained by determining the variability of the '0' calibrator and using the 2 $\sigma$  (95% certainty) statistic to calculate the minimum dose.

#### 14.3 Accuracy

The CA-125 AccuBind® ELISA test system was compared with a reference method. Biological specimens from low, normal, and elevated concentrations were assayed. The total number of such specimens was 121. The least square regression equation and the correlation coefficient were computed for CA-125 in comparison with the reference method. The data obtained is displayed in Table 4.

Method	Mean	Least Square Regression Analysis	Correlation Coefficient
This Method (X)	5.67	$y = -0.116 + 1.032x$	0.998
Reference (Y)	5.75		

#### 14.4 Specificity

In order to test the specificity of the antibody pair used, massive concentrations of possible cross-reactants were added to known serum pools and assayed in parallel with the base sera. In addition some widely used, over-the-counter, drugs and some cytotoxic drugs (10 fold the normal dose) were tested in the assay. No cross reaction was found. Percent recoveries for some of these additions are listed below in Table 5.

Analyte	Amount Added	% Recovery
Bilirubin	1 mMol/L	98 – 103%
Hemoglobin	1 mMol/L	100 – 106%
Triglycerides	10 mMol/L	96 – 110 %
RF	1000 kIU/L	97 – 107%
Biotin	25 $\mu$ g/L	99 – 103%

### 15.0 REFERENCES

1. Zarncheck N, *Adv Intern Med*, 19, 413 (1974).
2. Raynao G, Chu TM, *JAMA*, 220, 381 (1972).
3. Harrison, *Principles of Internal Medicine*, McGraw Hill Book Company, New York, 12<sup>th</sup> Ed (1991).
4. Wild D, *The Immunoassay Handbook*, Stockton Press, p444 (1994).
5. Hasholzner U, Steiber P, Baumgartner L, Pahl H, Meier W, Fateh-Moghadam A, "Methodological and clinical evaluation of three automated CA-125 assays compared with CA-125 II RIA (Centocor)", *Tumor Diagnosis & Ther*, 15, 114-117 (1994).
6. Hasholzner U, Steiber P, Baumgartner L, Pahl H, Meier W, Fateh-Moghadam A, "Clinical significance of the tumor markers CA-125 II and CA 72-4 in ovarian carcinoma", *Int J Cancer*, 69, 329-34 (1996).
7. Ovarian Cancer – NIH Consensus Conference, *JAMA*, 273, 491-497 (1995).
8. Daoud E, Bodor G, Weaver C, Landenson JH and Scott MG, "CA-125 concentrations in malignant and non-malignant disease", Washington University Case Conference, *Clin Chem*, 37, 1968-74 (1991).
9. De Bruijn HWA, Van Der Zee AGJ and Alders JG, "The value of Cancer Antigen 125 (CA-125) during treatment and follow up of patients with ovarian cancer", *Curr Opin Gynecol*, 9, 8-13 (1997).
10. Sikorska H, Schuster J, Gold P. "Clinical applications of Cancer Antigen 125", *Cancer Detection Preview*, 12, 321-355 (1988).
11. National Institute of Health, "Cancer Antigen 125: Its role as a marker in the management of cancer. A national Institute of Health Consensus Development Conference", *Ann Intern Med*, 94, 407-409 (1981).

Revision: 4 Date: 2019-Jul-16 DCO: 1353  
MP3025 Product Code: 3025-300

Size	96(A)	192(B)
A)	1ml set	1ml set
B)	1 (13ml)	2 (13ml)
C)	1 plate	2 plates
D)	1 (20ml)	1 (20ml)
E)	1 (7ml)	2 (7ml)
F)	1 (7ml)	2 (7ml)
G)	1 (8ml)	2 (8ml)

For Orders and Inquires, please contact

**Monobind Inc.**  
100 North Pointe Drive  
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Fax: +1 949.951.3539  
Mail: info@monobind.com Fax: www.monobind.com



Please visit our website to learn more about our products and services.

### Glossary of Symbols (EN 980/ISO 15223)

